Aurobindo Pharma Q2 Result: Profit Rises 9%, Missing Estimates
Aurobindo Pharma Ltd.'s second-quarter profit increased, missing analysts' estimates.
The Hyderabad-based bulk and generic drug maker's net profit increased 8% year-on-year to Rs 817 crore in the quarter ended Sept 30, 2024, according to an exchange filing. That compares with the Rs 972 crore consensus estimate of analysts tracked by Bloomberg.
Aurobindo Pharma Q2 FY25 Result Highlights (Year-on-Year)
Revenue up 8% at Rs 7,796 crore vs. Rs 7,219 crore (Bloomberg Estimate: Rs 7756 crore)
Ebitda up 12% at Rs 1,566 crore vs. Rs 1,402 crore (Bloomberg Estimate: Rs 1677 crore)
Ebitda margin at 20.1% vs. 19% (Bloomberg Estimate: 21.60%)
Net profit up 8.6% at Rs 817 crore vs. Rs 752 crore (Bloomberg Estimate Rs 972 crore)
Key Highlights
US Formulations
US revenue increased by 4.3% YoY to Rs 3,530 Cr and accounted for 45.3% of consolidated revenue.
Company filed 10 ANDAs with USFDA during the quarter.
The company has launched 14 products during the quarter.
Europe Formulations
Europe revenue increased by 19.0% YoY to Rs 2,105 crore and accounted for 27.0% of consolidated revenue.
Growth Markets Formulations
Growth Markets formulations revenue increased by 44.0% YoY to Rs 812 crore and accounted for 10.4% of consolidated revenue.
Domestic formulation sales for the quarter stood at Rs 71 crore.
Antiretroviral (ARV) Formulations
ARV business revenue decreased by 22.8% YoY to Rs 193 crore and accounted for 2.5% of consolidated revenue
Active Pharmaceutical Ingredients (API)
API business revenue remained flat YoY at Rs 1,156 Cr and contributed 14.8% of consolidated revenue.
"We are pleased with the continued growth in revenues across our key business areas this quarter, reflecting the resilience of our diversified portfolio. While profitability saw a slight dip, primarily due to the transient nature of certain business activities, our underlying performance remains strong, said Mr. K. Nithyananda Reddy, Vice Chairman and Managing Director of the Company.
With a solid foundation and ongoing operational improvements, we are confident of maintaining our growth trajectory and achieving our strategic objectives for the year." he added
Shares of Aurobindo Pharma closed 1.9% lower on Friday a day before the results were announced, compared to a 0.21% fall in the benchmark Nifty.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.